Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE: Intermittent vs Continuous Panitumumab + FOLFIRI in mCRC
NCT04425239Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2018
- Primary completion
- Jul 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in colorectal cancer (CRC), sponsored by National Cancer Institute. Started May 2018; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04425239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425239.